489427-26-1

Basic information

• Product Name: 17-(Fmoc-amino)-5-oxo-6-aza-3,9,12,15-tetraoxaheptadecanoic Acid
• Synonyms: 15-Oxo-5,8,11,17-Tetraoxa-2,14-diazanonadecanedioic Acid 1-(9H-Fluoren-9-ylmethyl)ester;17-(Fmoc-amino)-5-oxo-6-aza-3,9,12,15-tetraoxaheptadecanoic Acid
• CAS NO: 489427-26-1
• Molecular Formula: C27H34N2O9
• Molecular Weight: 530.57
• Product Categories: Fluorescent Labels and Indicators;Fluorescent Labels & Indicators
• Mol File: 489427-26-1.mol

Chemical Properties

• Boiling Point: 794.8°C at 760 mmHg
• Flash Point: 434.5°C
• Appearance: /
• Density: 1.256g/cm³
• Vapor Pressure: 1.22E-26mmHg at 25°C
• Refractive Index: 1.558
• CAS DataBase Reference: 17-(Fmoc-amino)-5-oxo-6-aza-3,9,12,15-tetraoxaheptadecanoic Acid(CAS DataBase Reference)
• NIST Chemistry Reference: 17-(Fmoc-amino)-5-oxo-6-aza-3,9,12,15-tetraoxaheptadecanoic Acid(489427-26-1)
• EPA Substance Registry System: 17-(Fmoc-amino)-5-oxo-6-aza-3,9,12,15-tetraoxaheptadecanoic Acid(489427-26-1)

Safety Data

• Hazardous Substances Data: 489427-26-1(Hazardous Substances Data)

Usage

Uses

Used in Medical Imaging:
17-(Fmoc-amino)-5-oxo-6-aza-3,9,12,15-tetraoxaheptadecanoic Acid is used as a contrast agent for optical imaging in the diagnosis of angiogenesis-related diseases. The fluorescein label attached to the molecule allows for enhanced visualization and detection of these conditions, improving the accuracy and efficiency of diagnostic procedures.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, 17-(Fmoc-amino)-5-oxo-6-aza-3,9,12,15-tetraoxaheptadecanoic Acid may be utilized in the development of new drugs targeting angiogenesis-related diseases. 17-(Fmoc-amino)-5-oxo-6-aza-3,9,12,15-tetraoxaheptadecanoic Acid's unique structure and properties make it a promising candidate for further research and potential therapeutic applications.
Used in Research and Development:
17-(Fmoc-amino)-5-oxo-6-aza-3,9,12,15-tetraoxaheptadecanoic Acid can also be employed in research and development for the study of angiogenesis and related biological processes. 17-(Fmoc-amino)-5-oxo-6-aza-3,9,12,15-tetraoxaheptadecanoic Acid's ability to serve as a contrast agent in optical imaging can provide valuable insights into the mechanisms underlying these conditions and contribute to the development of novel treatment strategies.

InChI:InChI=1/C27H34N2O9/c30-25(18-37-19-26(31)32)28-9-11-34-13-15-36-16-14-35-12-10-29-27(33)38-17-24-22-7-3-1-5-20(22)21-6-2-4-8-23(21)24/h1-8,24H,9-19H2,(H,28,30)(H,29,33)(H,31,32)

Upstream product

• 489427-25-0 17-amino-5-oxo-6-aza-3,9,12,15-tetraoxaheptadecanoic acid 
• 28920-43-6 (fluorenylmethoxy)carbonyl chloride 
• 134179-38-7 2-(2-(2-(2-azidoethoxy)ethoxy)ethoxy)ethylamine 
• 112-60-7 Tetraethylene glycol 
• 239081-53-9 17-azido-5-oxo-6-aza-3,9,12,15-tetraoxaheptadecanoic acid 
• 101187-39-7 1,11-diazido-3,6,9-trioxaundecane 
• 82911-69-1 N-(9H-fluoren-2-ylmethoxycarbonyloxy)succinimide 
• 929-75-9 2-[2-[2-[2-aminoethoxy]ethoxy]ethoxy]ethylamine 

Relevant articles and documents

Radiopharmaceutical compositions

The present invention relates to 99mTc-maraciclatide radiopharmaceutical compositions, which are stabilised with a radioprotectant. Also described are kits for the preparation of the radiopharmaceutical compositions, as well methods of preparin

Synthesis and in vitro and in vivo evaluation of SiFA-tagged bombesin and RGD peptides as tumor imaging probes for positron emission tomography

Gastrin-releasing-peptide (GRP)-receptors and ?± v?3-integrins are widely discussed as potential target structures for oncological imaging with positron emission tomography (PET). Favored by the overexpression of receptors on the surface of tumor cells good imaging characteristics can be achieved with highly specific radiolabeled receptor ligands. PEGylated bombesin (PESIN) derivatives as specific GRP receptor ligands and RGD (one-letter codes for arginine-glycine-aspartic acid) peptides as specific ?±v?3 binders were synthesized and tagged with a silicon-fluorine-acceptor (SiFA) moiety. The SiFA synthon allows for a fast and highly efficient isotopic exchange reaction at room temperature giving the [18F]fluoride labeled peptides in up to 62% radiochemical yields (d.c.) and a‰￥ 99% radiochemical purity in a total synthesis time of less than 20 min. Using nanomolar quantities of precursor high specific activities of up to 60 GBq ?mol-1 were obtained. To compensate the high lipophilicity of the SiFA moiety various hydrophilic structure modifications were introduced leading to significantly reduced logD values. Competitive displacement experiments with the PESIN derivatives showed a 32 to 6 nM affinity to the GRP receptor on PC3 cells, and with the RGD peptides a 7 to 3 ?M affinity to the ?± v?3 integrins on U87MG cells. All derivatives proved to be stable in human plasma over at least 120 min. Small animal PET measurements and biodistribution studies revealed an enhanced and specific accumulation of the RGD peptide 18F-SiFA-LysMe3-?- carboxy-d-Glu-RGD (17) in the tumor tissue of U87MG tumor-bearing mice of 5.3% ID/g whereas the PESIN derivatives showed a high liver uptake and only a low accumulation in the tumor tissue of PC3 xenografts. Stability studies with compound 17 provided further information on its metabolism in vivo. These results altogether demonstrate that the reduction of the overall lipophilicity of SiFA tagged RGD peptides is a promising approach for the generation of novel potent 18F-labeled imaging agents.

OPTICAL IMAGING

This invention relates to a method for imaging of wet age-related macular degeneration (AMD) using a contrast agent comprising a vector attached to an optical imaging reporter, wherein the vector has affinity for receptors associated with angiogenesis. Th

IMAGING AGENTS WITH IMPROVED PHARMACOKINETIC PROFILES

The invention relates to compounds suitable for use in an imaging agent said imaging agent showing an improved pharmacokinetic profile.